KRUK PDRA, Kidney Genetics Group, Division of Clinical Medicine, School of Medicine and Population Health
I joined the Kidney Genetics Group at The University of Sheffield in 2019. My research has been centered around the functional characterization of genomic, transcriptomic, and proteomic changes observed in cellular and experimental models of Autosomal dominant polycystic kidney disease (ADPKD).
2019 - Present: KRUK and PKDF Postdoctoral Researcher, School of Medicine and Population Health, University of Sheffield, UK.
2018 - 2019: Bioinformatician, Medical School, University of Sheffield, UK.
2014 - 2018: PhD Molecular Biology and Biotechnology, Faculty of Science, University of Sheffield, UK.
2013 - 2013: YCR Research Assistant, Medical School, University of Sheffield, UK.
2011 - 2012: Vinnova Research Engineer, Biotechnology Department, KTH Royal Institute of Technology, SWEDEN.
2009 - 2010: Research Technician, Medical School, University of Sheffield, UK.
2007 - 2008: MSc Stem Cell and Regenerative Medicine, Faculty of Science, University of Sheffield, UK.
2003 - 2007: B.Eng. Biotechnology, School of Bioengineering, SRM University, Chennai, INDIA.
I obtained my PhD in Molecular Biology at The University of Sheffield where I developed a keen interest in functional genomics and bioinformatics. I pursue this interest at Kidney Genetics Group where I am currently a KRUK Postdoctoral Research Associate. In addition to my research activities, I dedicate myself to teaching modules MED6003 and 6071 within the MSc Molecular Medicine program.
For my updated and full list of publications, please see my ORCiD:-
Valluru MK, Chung NK, Gilchrist M, et al. A founder UMOD variant is a common cause of hereditary nephropathy in the British population. J Med Genet. 2023;60(4):397-405.
Puppo M, Valluru MK, Croset M, et al. MiR-662 is associated with metastatic relapse in early-stage breast cancer and promotes metastasis by stimulating cancer cell stemness. Br J Cancer. 2023;129(5):754-771.
Puppo M, Valluru MK, Clézardin P. Chapter 33, MicroRNAs and bone metastasis: how small RNAs regulate secondary tumour formation and progression in the skeleton. Dominique Heymann (ed.) Bone Cancer 3E. Elsevier 2022.
Durkie M, Chong J, Valluru MK, Harris PC, Ong ACM. Biallelic inheritance of hypomorphic PKD1 variants is highly prevalent in very early onset polycystic kidney disease. Genet Med. 2021;23(4):689-697.
Lannoy M, Valluru MK, Chang L, et al. The positive effect of selective prostaglandin E2 receptor EP2 and EP4 blockade on cystogenesis in vitro is counteracted by increased kidney inflammation in vivo. Kidney Int. 2020;98(2):404-419.
Dardente H, English WR, Valluru MK, Kanthou C, Simpson D. Debunking the Myth of the Endogenous Antiangiogenic Vegfaxxxb Transcripts. Trends Endocrinol Metab. 2020;31(6):398-409.
Doherty RE, Bryant HE, Valluru MK, Rennie IG, Sisley K. Increased Non-Homologous End Joining Makes DNA-PK a Promising Target for Therapeutic Intervention in Uveal Melanoma. Cancers (Basel). 2019;11(9):1278. Published 2019 Aug 30.
Valluru MK et al., (2019) VEGFA isoform switching in soft tissue sarcoma is associated with decreased survival. International journal of experimental pathology. 100 (4), A41-A41.
Valluru MK & Sorefan K. (2019) Control of stem cell niche and fruit development in Arabidopsis thaliana by AGO10/ZWL requires the bHLH transcription factor INDEHISCENT. Development biology. bioRxiv.
Carolina Å, Linn W, Erika H, Valluru MK. et al., “Longitudinal Study of Neurosphere Metabolism in Bioreactor Culture for Scalable Production of Human Embryonic Stem Cell-Derived Neurons”. 4th International Conference on Stem Cell Engineering (2014). American Institute of Chemical Engineers.
Valluru MK, Staton CA, Reed MW, Brown NJ. Transforming Growth Factor-β and Endoglin Signaling Orchestrate Wound Healing. Front Physiol. 2011;2:89. Published 2011 Nov 29.
Valluru MK, Brown NJ, Cross SS, Reed MW, Staton CA. Blood vessel characterization in human dermal wound repair and scarring. Br J Dermatol. 2011;165(1):221-224.
Valluru MK et al., (2010) Class 3 semaphorins and their plexin receptors in human dermal wound healing & Class 3 semaphorins inhibit angiogenic activity in vitro. Microcirculation 17:485 PC50&51.